Sunshine Biopharma Inc. (OTC PINK: SBFM), the stock slipped -3.59% to $0.2420 at the previous close. Stocks last month’s performance was recorded 868.00% versus 3-month Performance of 1 628.57%.In the previous trading session Company’s $6.76M.
Besides working on COVID-19, Sunshine Biopharma Inc. (OTC PINK: SBFM), is developing a unique anticancer compound, Adva-27a. The efficacy of Adva-27a has been demonstrated in destroying multidrug-resistant cancer cells, such as pancreatic cancer, lung cancer, breast cancer, and uterine sarcoma.
February 10, 2021, A Transgenic Mice Study of its COVID-19 treatment has been initiated by Sunshine Biopharma Inc. (OTC PINK: SBFM). The drug has been under development since May of last year. COVID-19 works by inhibiting an enzyme that is instrumental in infecting a person’s immune system, influencing their immunity. A study on mice is currently taking place at the University of Georgia’s College of Pharmacy.
Researchers have genetically modified laboratory mice to express the transmembrane protein for the SARS-CoV-2 that causes COVID-19, making them susceptible to lethal infection by the viral agent that causes COVID-19. The SARS-CoV-2 virus infects human cells via the hACE2 receptor. Sunshine Biopharma’s protease inhibitors are being examined for their ability to protect hACE2-transgenic mice from disease progression and death due to SARS-CoV-2 infection.
The Sunshine Biopharma CEO Dr. Steve Slilaty said that if the mice studies proved successful, the results would be submitted to the FDA seeking authorization to conduct Phase I clinical trials involving actual COVID-19 patient volunteers. In partnership with the University of Georgia, The Company is excited to show this pivotal study on transgenic mice. Several COVID-19 variants are emerging worldwide that are more virulent and may evade neutralisation by current vaccines.
Company’s Covid-19 Focus
The SARS-CoV-2 is the etiological agent of the ongoing COVID-19 pandemic, which killed more than 2.3 million people since it first appeared in December 2019. In people infected with the illness, there are currently no drugs that effectively arrest viral replication. Sunny Biopharma filed a provisional patent application on May 22, 2020, for several molecules that were designed by computer-aided modeling to inhibit Coronavirus proteases, thus preventing the virus from multiplying. A lead compound, SBFM-PL4, has been identified by Sunshine Biopharma after synthesizing four such molecules. Collaboration with the University of Georgia College of Pharmacy is moving SBFM-PL4 through in vitro testing, followed by animal studies involving mice, now ongoing, before entering clinical trials involving COVID-19 patients.